RGLS regulusrx.com: Business Value to Revenue

Public company logo of Regulus Therapeutics, Inc. (RGLS)

Regulus Therapeutics (RGLS) develops miRNA-based drugs to treat polycystic kidney disease, leveraging unique patents to drive future FCF growth. However, success depends on regulatory approvals and the volume of R&D reserves. The current EV/Sales ratio reflects market expectations, where the value of characterizes this level. Since there are no commercial products, the company remains in a phase of pure capital consumption without operational inertia.

RGLS Regulus Therapeutics, Inc. Enterprise Value-to-Revenue Ratio (07/04/2022 - 11/19/2026)

Financial and market metric breakdowns for Regulus Therapeutics, Inc. (RGLS)

- price and consensus price forecast:
Fundamental valuation:Regulus Therapeutics (RGLS)
Core merchandise of Regulus Therapeutics Inc.

This indicator compares the total enterprise value with the volume of generated sales, excluding the impact of debt load to identify the real market valuation of assets. The integration of green chemistry principles into the RNA therapeutics of Regulus Therapeutics (RGLS) affects operating expenses, which is reflected in the EV/Sales multiple trend, allowing investors to judge the capitalization efficiency of environmental initiatives and overall capital sustainability.

Competitor analysis for Regulus Therapeutics

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Enterprise Value-to-Revenue Ratio Bionano Genomics BNGO|Business Value to Revenue APDN|BLUE - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume IPA|Omega Therapeutics, Inc. (OMGA) - Enterprise Value-to-Revenue Ratio|Singular Genomics Corp (OMIC) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple